Cybrexa Therapeutics' Series B - II Round

Cybrexa Therapeutics raised a round of funding on September 21, 2018. Investors include HighCape Partners.

Cybrexa Therapeutics is a biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment.…

Articles about Cybrexa Therapeutics' Series B - II Round: